

Special Issue

Nanomaterials for Cancer Photothermal Therapy

Message from the Guest Editor

Nanomaterials with specific properties can reach the tumor site and produce, upon interaction with laser radiation, a temperature increase that can damage cancer cells. For this purpose, NIR light is generally used due to its minimal interaction with biological components, ensuring a high tissue penetration depth and reduced off-target heating. Hence, nanomaterials with a high NIR absorption have been extensively investigated for cancer photothermal therapy. On the other hand, the assembly of nanostructures with NIR-absorbing materials has also been explored. The nanomaterials' photoinduced heat can also trigger other events like release of encapsulated agents, opening a venue for combining nanomaterials' mediated photothermal therapy with other therapeutic modalities. This Special Issue focuses on nanomaterials aimed for cancer photothermal therapy. Research articles covering the synthesis/formulation of novel NIR-light-responsive nanomaterials, their functionalization and characterization, as well as their application in cancer combination therapy are welcome. Comprehensive reviews are also welcomed.

Guest Editor

Dr. Duarte De Melo-Diogo

CICS-UBI – Centro de Investigação em Ciências da Saúde,
Universidade da Beira Interior, Avenida Infante D. Henrique, 6200-506
Covilhã, Portugal

Deadline for manuscript submissions

closed (10 November 2021)



Pharmaceutics

an Open Access Journal
by MDPI

Impact Factor 5.5
CiteScore 10.0
Indexed in PubMed



mdpi.com/si/62918

Pharmaceutics
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
pharmaceutics@mdpi.com

[mdpi.com/journal/
pharmaceutics](https://mdpi.com/journal/pharmaceutics)





Pharmaceutics

an Open Access Journal
by MDPI

Impact Factor 5.5
CiteScore 10.0
Indexed in PubMed



[mdpi.com/journal/
pharmaceutics](https://mdpi.com/journal/pharmaceutics)



About the Journal

Message from the Editor-in-Chief

Pharmaceutics (ISSN 1999-4923) is an online open access journal on the science and technology of pharmaceuticals and biopharmaceuticals. The scientific community, the wider community and the general public have unlimited and free access to the content as soon as a paper is published; this open access to your research ensures your findings are shared with the widest possible audience. Please consider publishing your impressive work in this high quality journal. We would be pleased to welcome you as one of our authors.

Editor-in-Chief

Prof. Dr. Patrick J. Sinko
Department of Pharmaceutics, Ernest Mario School of Pharmacy,
Rutgers University, Piscataway, NJ 08854, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1
(Pharmaceutical Science)

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 14.9 days after submission; acceptance to publication is undertaken in 3.3 days (median values for papers published in this journal in the first half of 2025).